Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
GlobalData on MSN6d
FDA expands Enhertu approval to include HER2-ultralow breast cancer patientsAstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...
GlobalData on MSN5d
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEODaiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...
AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback